Impaired brain dopamine transporter in chemobrain patients submitted to brain SPECT imaging using the technetium-99m labeled tracer TRODAT-1
- 53 Downloads
“Chemobrain” is a medical secondary effect of cancer chemotherapy treatment characterized by a general decline in cognition affecting visual and verbal memory, attention, complex problem-solving skills, and motor function. Dopamine (DA) central nervous system neurotransmitters serve an important role in cognition, and changes in DA could potentially explain impaired cognition associated with chemotherapy. Therefore, our objective was to assess in vivo dopaminergic dysfunction in the central nervous system (CNS) of a group of female breast cancer survivors with cognitive impairment following chemotherapy.
Twenty-eight women reporting chemobrain were recruited for this study and compared to 22 healthy reference women. Striatal dopamine transporter (DAT) binding ratio was determined by 99mTc-TRODAT-1 (a highly selective radiotracer for DAT in the dorsal striatum) single-photon emission computed tomography and a quantitative evaluation was obtained by DatQUANT™ software (GE Healthcare). The DAT binding ratio (BRDAT) in the patient and control groups was compared using the Student’s t test, a multivariate analysis of variance (MANOVA) was used to compare age, years of schooling and BRDAT. The relationship between continuous variables, such as cognitive impairment and BRDAT was assessed using Pearson correlation test.
There was a difference in BRDAT between the chemobrain patients and control group. Patients had statistically significant (p < 0.05) lower concentrations of the radiopharmaceutical in the striatum.
We identified a significant dopaminergic decrease in all regions of the dorsal striatum within the patients reporting cognitive dysfunction after chemotherapy. Therefore, our results indicate a possible role of dopamine transporter in the physiopathology of chemobrain, even out of the acute phase of symptoms.
KeywordsDopamine transporter SPECT Chemobrain Chemotherapy TRODAT-1
We are grateful to the Hospital Pérola Byington, Sāo Paulo, Brazil, and MD Anderson Cancer Center, Houston.
Hospital Israelita Albert Einstein.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflicts of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Informed consent Informed consent was obtained from all individual participants or legitimate representatives included in the study.
Informed consent was obtained from all individual participants included in this study.
- 4.Argyriou AA, Assimakopoulos K, Iconomou G, Giannakopoulou F, Kalofonos HP. Either called “chemobrain” or “chemofog,” the long-term chemotherapy-induced cognitive decline in cancer survivors is real. J Pain Symptom Manag. 2011;41(1):126–39.Google Scholar
- 11.von Zglinicki T. Oxidative stress shortens telomeres. Trends Biochem Sci. 2002;27(7):339–44.Google Scholar
- 13.Kelley KW, Bluthe RM, Dantzer R, Zhou JH, Shen WH, Johnson RW, et al. Cytokine-induced sickness behavior. Brain Behav Immun. 2003;17(Suppl 1):112-8.Google Scholar
- 26.Wagner LISJ, Butt Z, Lai JS, Cella D. Measuring patient self-reported cognitive function: development of the functional assessment of cancer therapy–cognitive function instrument. J Support Oncol. 2009;7:W32–W9.Google Scholar
- 39.Von Ah D, Tallman EF. Perceived cognitive function in breast cancer survivors: evaluating relationships with objective cognitive performance and other symptoms using the functional assessment of cancer therapy-cognitive function instrument. J Pain Symptom Manag. 2015;49(4):697–706.Google Scholar
- 40.Tanimukai H. Prevalence of cognitive impairments following chemotherapy and its relationship to depression in Japanese breast cancer survivors: an exploratory study. Int J Complement Altern Med. 2018;11(2):145–9.Google Scholar
- 49.Yin TK, Lee BF, Yang YK, Chiu NT. Differences of various region-of-interest methods for measuring dopamine transporter availability using 99mTc-TRODAT-1 SPECT. Sci World J. 2014;2014:837439.Google Scholar
- 51.Briones TWJ, Wadowska M. Chronic neurpinflammation and cognitive impairment following transient global cerebral eschemia: role of fractalkine/CX3CR1signaling. J Neuroinflammation. 2014;11:3.Google Scholar
- 53.Aluise CD, Miriyala S, Noel T, Sultana R, Jungsuwadee P, Taylor TJ, et al. 2-Mercaptoethane sulfonate prevents doxorubicin-induced plasma protein oxidation and TNF-alpha release: implications for the reactive oxygen species-mediated mechanisms of chemobrain. Free Radic Biol Med. 2011;50(11):1630–8.PubMedGoogle Scholar
- 56.Deprez SAF, Yigit R, et al. Chemotherapy-induced structural changes in cerebral white matter its correlation with impaired cognitive functioning in breast cancer patients. Hum Brain Mapp. 2011;32:580–493.Google Scholar